Automated Line-of-Therapy Algorithm for Adults with Metastatic Non-Small Cell Lung Cancer: Validation Study Using Blinded Manual Chart Review (Preprint)

2021 ◽  
Author(s):  
Weilin Meng ◽  
Kelly M Mosesso ◽  
Kathleen A Lane ◽  
Anna R Roberts ◽  
Ashley Griffith ◽  
...  

BACKGROUND Extraction of line of therapy (LOT) information from electronic health record (EHR) and claims data is essential for determining longitudinal changes in systemic anticancer therapy (SACT) in real-world clinical settings. OBJECTIVE The aim of this retrospective cohort analysis was to validate and refine our previously described open source LOT algorithm by comparing algorithm output with results obtained through blinded manual chart review. METHODS We used structured EHR data and clinical documents to identify 500 adult patients treated for metastatic non-small cell lung cancer with SACT from 2011 through mid-2018, assigning patients to training (n=350) and test cohorts (n=150), randomly divided proportional to the overall ratio of simple:complex cases (n=254:246). Simple cases were patients who received one LOT and no maintenance therapy; complex cases received more than one LOT and/or maintenance therapy. Algorithmic changes were performed using the training cohort data, after which the refined algorithm was evaluated against the test cohort. RESULTS For the simple cases, 16 instances of discordance between LOT algorithm and chart review pre-refinement were reduced to 8 instances post-refinement; in the test cohort there was no discordance between algorithm and chart review. For the complex cases, algorithm refinement reduced discordance from 68 to 62 instances, with 37 instances in the test cohort. Percentage agreement between LOT algorithm output and chart review for patients who received one LOT was 89% pre-refinement, 93% post-refinement, and 93% for the test cohort, while the likelihood of precise matching between algorithm output and chart review decreased with increasing number of unique regimens. Several areas of discordance that arose from differing definitions of LOTs and maintenance therapy could not be objectively resolved because of a lack of precise definitions in the medical literature. CONCLUSIONS Our findings identify common sources of discordance between an LOT algorithm and clinician documentation, providing for the possibility of targeted algorithm refinement.


2019 ◽  
Vol 15 (1) ◽  
pp. 50-55
Author(s):  
Ahmed Nagy ◽  
Omar Abdel Rahman ◽  
Heba Abdullah ◽  
Ahmed Negida

Background: Although well established for the effective management of hematologic cancers, maintenance chemotherapy has only been recently incorportated as a treatment paradigm for advanced non–small-cell lung cancer. Maintenance chemotherapy aims to prolong a clinically favorable response state achieved after finishing induction therapy which is usually predefined in number before startng treatment. There are 2 modalities for maintenance therapy; continuation maintenance (involving a non-platinum component which was a part of the induction protocol or a targeted agent) and switch maintenance therapy (utilizing a new agent which was not a part of the induction regimen). Methods: The purpose of this article is to review the role of maintenance therapy in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC) and provide a brief overview about induction chemotherapy in NSCLC to address the basis of maintenance therapy as a treatment option. We will also compare the impact of maintenance chemotherapy with the now evolving role of immunotherapy in NSCLC. Results: There have been 4 maintenance studies to date showing prolonged PFS and OS with statistical significance. However, Three out of the four studies (ECOG4599, JMEN, and PARAMOUNT) did not report tumor molecular analysis. As regard Immunotherapy, current data is in favour of strongly an increasing role for immunotherapy in NSCLC. Conclusion: Maintenance therapy in NSCLC continues to be an important therapeutic line to improve outcome in patients with metastatic and recurrent disease.



2011 ◽  
Vol 22 (10) ◽  
pp. 1010-1019 ◽  
Author(s):  
Fausto Petrelli ◽  
Karen Borgonovo ◽  
Mary Cabiddu ◽  
Sandro Barni


2012 ◽  
Vol 9 (1) ◽  
pp. 77-86
Author(s):  
Cesare Gridelli ◽  
Paolo Maione ◽  
Antonio Rossi ◽  
Clorinda Schettino ◽  
Maria Anna Bareschino ◽  
...  




Author(s):  
C Carriles Fernández ◽  
I Zapico García ◽  
R Jiménez Galán ◽  
A Llorente Romeo ◽  
A Martínez Torrón ◽  
...  




Sign in / Sign up

Export Citation Format

Share Document